This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
While the pharmaceutical industry has historically lagged behind other industries in the overall shift to programmatic advertising, the pandemic accelerated this transformation to emerging channels like connected TV (CTV).
Canary Wharf’s bid to become a new hub for the life sciences sector in the UK has been given a boost following the decision by Genomics England to relocate to the development. The organisation – which analyses sequenced genomes for the NHS and helps researchers access and use data to help identify the causes of disease – will “anchor” the new cluster, according to Canary Wharf Group (CWG), which is behind the initiative.
Makar discusses the significance of AstraZeneca’s diabetes and heart failure drug Forxiga (dapagliflozin) for the treatment of chronic kidney disease (CKD).
ADC Therapeutics is looking to add a second approved antibody-drug conjugate to its portfolio after reporting strong phase 2 results with camidanlumab tesirine (cami) in relapsed/refractory Hodgkin lymphoma at the EHA annual meeting. In the study, 70% of patients treated with the CD25-targeting ADC had a response to therapy, with 33% of them having a complete response – in other words their cancer went into remission – with a median response time of 13.7 months.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
By Ryan Payne, PharmD. Because of the insidious nature of chronic kidney disease, and because most people affected do not have symptoms until the condition becomes advanced, it is sometimes under-recognized by busy healthcare providers. According to the National Kidney Foundation, kidney disease affects an estimated 37 million people in the United States.
The patient recruitment solutions company plans to work with the charity to support research and clinical trials through a range of fundraising activities.
Kraus brings more than 25 years of experience leading life sciences companies, including global responsibility for customer strategy, sales, operations, and various support functions.
An expert from the trial tech company discusses tools that can prove useful for trial teams looking to avoid employee shortages plaguing other industries.
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
SAE Media Group’s 2nd Annual Biosensors for Medical Wearables. *In collaboration with Medical Design Briefs*. 24th – 25th October 2022 | Boston, MA, USA. Sponsored by: Raumedic. [link]. Advances in development and therapeutic applications of on-body sensors. SAE Media Group is proud to present the Biosensors for Medical Wearables Conference, taking place on the 24th – 25th October 2022.
RESEARCH TRIANGLE PARK, NC: 13 June 2022. Syner-G BioPharma Group (“Syner-G”), a leading provider of consulting services to pharmaceutical and biotechnology clients, today announced that Ron Kraus has joined the company as Chief Executive Officer (CEO). Mr. Kraus has more than 25 years of experience leading life sciences companies, including global responsibility for customer strategy, sales, operations, and various support functions.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
RESEARCH TRIANGLE PARK, NC: 13 June 2022 Syner-G BioPharma Group (“Syner-G”), a leading provider of consulting services to pharmaceutical and biotechnology clients, today announced that Ron Kraus has joined the company as Chief Executive Officer (CEO). Mr. Kraus has more than 25 years of experience leading life sciences companies, including global responsibility for customer strategy, […].
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
The new user experience improvements will make it easier for members to discover and interact with relevant products related to their medical specialty.
Parisa “Risa” Vatanka, PharmD, CTTS, senior director of corporate alliances at the American Pharmacists Association (APhA), tells us about the ideal role of pharmacists in patient care and their effort to gain provider status. . Pharmacists are the most accessible, most frequently visited healthcare providers, but despite their contribution to supporting communities’ health, pharmacists lack provider status recognition to be appropriately compensated for their services. “
An analysis of images of the retina harvested from the UK Biobank resource suggests that it may be possible to identify individuals at risk of coronary artery disease by examining the pattern of blood vessels in the retina during an eye test. The researchers combined data from the branching of blood vessels in the retina with genetic data in the study, which was presented today at the European Society of Human Genetics.
Amylyx Pharmaceuticals’ efforts to bring its amyotrophic lateral sclerosis therapy AMX0035 to market in the US have run into some roadblocks, so an approval by Health Canada is a welcome relief for the biotech. Canada is the first country worldwide to approve the combination of orally active ingredients sodium phenylbutyrate and taurursodiol – as Albrioza – marking Amylyx’ transition from a development-stage to a commercial-stage company.
Three years after Daiichi Sankyo’s FLR3 inhibitor quizartinib was rejected by the FDA, the drugmaker has reported the results of a new phase 3 trial that is key to getting the drug to the US market and chasing down rival drugs from Astellas and Novartis. Data from the QuANTUM-First trial presented at the EHA congress showed that quizartinib more than doubled the median overall survival when added to first-line chemotherapy in patients with newly-diagnosed, FLT3-ITD-positive acute myeloid l
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content